277 related articles for article (PubMed ID: 19879424)
21. miRNA-378 reverses chemoresistance to cisplatin in lung adenocarcinoma cells by targeting secreted clusterin.
Chen X; Jiang Y; Huang Z; Li D; Chen X; Cao M; Meng Q; Pang H; Sun L; Zhao Y; Cai L
Sci Rep; 2016 Jan; 6():19455. PubMed ID: 26781643
[TBL] [Abstract][Full Text] [Related]
22. Interleukin-6 affects cell death escaping mechanisms acting on Bax-Ku70-Clusterin interactions in human colon cancer progression.
Pucci S; Mazzarelli P; Sesti F; Boothman DA; Spagnoli LG
Cell Cycle; 2009 Feb; 8(3):473-81. PubMed ID: 19177010
[TBL] [Abstract][Full Text] [Related]
23. sCLU regulates cisplatin chemosensitivity of lung cancer cells in vivo.
Ma G; Cai H; Gao L; Wang M; Wang H
World J Surg Oncol; 2015 Feb; 13():80. PubMed ID: 25884382
[TBL] [Abstract][Full Text] [Related]
24. Challenge and promise: roles for clusterin in pathogenesis, progression and therapy of cancer.
Shannan B; Seifert M; Leskov K; Willis J; Boothman D; Tilgen W; Reichrath J
Cell Death Differ; 2006 Jan; 13(1):12-9. PubMed ID: 16179938
[TBL] [Abstract][Full Text] [Related]
25. sCLU as prognostic biomarker and therapeutic target in osteosarcoma.
Ma J; Gao W; Gao J
Bioengineered; 2019 Dec; 10(1):229-239. PubMed ID: 31117872
[TBL] [Abstract][Full Text] [Related]
26. mda-7/IL-24 differentially regulates soluble and nuclear clusterin in prostate cancer.
Bhutia SK; Das SK; Kegelman TP; Azab B; Dash R; Su ZZ; Wang XY; Rizzi F; Bettuzzi S; Lee SG; Dent P; Grant S; Curiel DT; Sarkar D; Fisher PB
J Cell Physiol; 2012 May; 227(5):1805-13. PubMed ID: 21732348
[TBL] [Abstract][Full Text] [Related]
27. Repression of IR-inducible clusterin expression by the p53 tumor suppressor protein.
Criswell T; Klokov D; Beman M; Lavik JP; Boothman DA
Cancer Biol Ther; 2003; 2(4):372-80. PubMed ID: 14508108
[TBL] [Abstract][Full Text] [Related]
28. Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapy.
Sowery RD; Hadaschik BA; So AI; Zoubeidi A; Fazli L; Hurtado-Coll A; Gleave ME
BJU Int; 2008 Aug; 102(3):389-97. PubMed ID: 18336596
[TBL] [Abstract][Full Text] [Related]
29. siRNA-directed clusterin silencing promotes cisplatin antitumor activity in human non-small cell lung cancer xenografts in immunodeficient mice.
Zhang B; Liu ZM; Hao FG; Wang M
Eur Rev Med Pharmacol Sci; 2014 Jun; 18(11):1595-601. PubMed ID: 24943969
[TBL] [Abstract][Full Text] [Related]
30. Overexpression of clusterin correlates with tumor progression, metastasis in gastric cancer: a study on tissue microarrays.
Bi J; Guo AL; Lai YR; Li B; Zhong JM; Wu HQ; Xie Z; He YL; Lv ZL; Lau SH; Wang Q; Huang XH; Zhang LJ; Wen JM; Guan XY
Neoplasma; 2010; 57(3):191-7. PubMed ID: 20353268
[TBL] [Abstract][Full Text] [Related]
31. RNA interference-mediated secretory clusterin gene silencing inhibits proliferation and promotes apoptosis of human non-small cell lung cancer cells.
Yan Y; Luo K; Zhang H; Chai W
Hepatogastroenterology; 2013; 60(121):70-5. PubMed ID: 22975582
[TBL] [Abstract][Full Text] [Related]
32. IR-inducible clusterin gene expression: a protein with potential roles in ionizing radiation-induced adaptive responses, genomic instability, and bystander effects.
Klokov D; Criswell T; Leskov KS; Araki S; Mayo L; Boothman DA
Mutat Res; 2004 Dec; 568(1):97-110. PubMed ID: 15530543
[TBL] [Abstract][Full Text] [Related]
33. Intracellular clusterin negatively regulates ovarian chemoresistance: compromised expression sensitizes ovarian cancer cells to paclitaxel.
Hassan MK; Watari H; Christenson L; Bettuzzi S; Sakuragi N
Tumour Biol; 2011 Oct; 32(5):1031-47. PubMed ID: 21761117
[TBL] [Abstract][Full Text] [Related]
34. Clusterin isoforms differentially affect growth and motility of prostate cells: possible implications in prostate tumorigenesis.
Moretti RM; Montagnani Marelli M; Mai S; Cariboni A; Scaltriti M; Bettuzzi S; Limonta P
Cancer Res; 2007 Nov; 67(21):10325-33. PubMed ID: 17974975
[TBL] [Abstract][Full Text] [Related]
35. eIF3f reduces tumor growth by directly interrupting clusterin with anti-apoptotic property in cancer cells.
Lee JY; Kim HJ; Rho SB; Lee SH
Oncotarget; 2016 Apr; 7(14):18541-57. PubMed ID: 26988917
[TBL] [Abstract][Full Text] [Related]
36. Tumor-derived secretory clusterin induces epithelial-mesenchymal transition and facilitates hepatocellular carcinoma metastasis.
Wang C; Jiang K; Kang X; Gao D; Sun C; Li Y; Sun L; Zhang S; Liu X; Wu W; Yang P; Guo K; Liu Y
Int J Biochem Cell Biol; 2012 Dec; 44(12):2308-20. PubMed ID: 23010347
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic targeting of myeloid-derived suppressor cells involves a novel mechanism mediated by clusterin.
Zhou J; Donatelli SS; Gilvary DL; Tejera MM; Eksioglu EA; Chen X; Coppola D; Wei S; Djeu JY
Sci Rep; 2016 Jul; 6():29521. PubMed ID: 27405665
[TBL] [Abstract][Full Text] [Related]
38. Novel nucleolar localization of clusterin and its associated functions in human oral cancers: An in vitro and in silico analysis.
Kadam R; Harish M; Dalvi K; Teni T
Cell Biochem Funct; 2021 Apr; 39(3):380-391. PubMed ID: 33155695
[TBL] [Abstract][Full Text] [Related]
39. Silencing of secretory clusterin sensitizes NSCLC cells to V-ATPase inhibitors by downregulating survivin.
Kim YS; Jin HO; Hong SE; Song JY; Hwang CS; Park IC
Biochem Biophys Res Commun; 2018 Jan; 495(2):2004-2009. PubMed ID: 29253572
[TBL] [Abstract][Full Text] [Related]
40. Development of resistance to chemotherapeutic drugs in human osteosarcoma cell lines largely depends on up-regulation of Clusterin/Apolipoprotein J.
Lourda M; Trougakos IP; Gonos ES
Int J Cancer; 2007 Feb; 120(3):611-22. PubMed ID: 17096323
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
